Global RSV Diagnostics Market Size study & Forecast, by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA), Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare)

The Global RSV Diagnostics Market, valued at approximately USD 6.27 billion in 2024, is projected to advance at a robust CAGR of 5.81% between 2025 and 2035. Respiratory Syncytial Virus (RSV) is a pervasive pathogen that significantly impacts pediatric, geriatric, and immunocompromised populations, causing a substantial burden on healthcare systems worldwide. The rising global awareness of RSV’s severe clinical implications, coupled with intensified initiatives to strengthen early detection capabilities, has catapulted the demand for advanced diagnostic solutions. Modern RSV diagnostic technologies, particularly molecular-based platforms and high-sensitivity immunoassays, are increasingly being adopted in both hospital and point-of-care settings to reduce diagnostic turnaround times, improve patient triage, and facilitate timely intervention. The growing integration of automation and AI-driven interpretation tools into RSV diagnostic workflows is further enhancing accuracy and scalability, positioning the market for sustained expansion.

The surge in RSV incidence rates—exacerbated by seasonal outbreaks and fluctuating immunity patterns—has pushed laboratories and clinical facilities to upgrade testing capabilities. This trend is particularly evident in regions experiencing post-pandemic respiratory infection rebounds, where timely detection is critical to mitigating hospital overcrowding. According to data from the U.S. Centers for Disease Control and Prevention, RSV-associated hospitalizations in older adults surged significantly in recent winters, highlighting the urgent need for scalable and reliable testing infrastructure. Furthermore, advances in multiplex testing, which allow simultaneous screening for RSV alongside influenza and SARS-CoV-2, are expanding the value proposition of RSV diagnostics for both healthcare providers and patients. However, market growth could face headwinds from cost constraints in low-resource healthcare settings, as well as limited availability of trained personnel to operate advanced diagnostic platforms.

Regionally, North America currently commands a dominant share of the RSV diagnostics market, bolstered by strong public health surveillance programs, well-developed healthcare infrastructure, and proactive adoption of molecular diagnostics. The region also benefits from extensive R&D investment and frequent product launches by leading diagnostic manufacturers. Europe follows closely, driven by government-backed screening programs, strong adoption of point-of-care testing, and rising RSV awareness among clinicians and the general public. In contrast, Asia Pacific is expected to be the fastest-growing market through 2035, fueled by expanding healthcare access, rising pediatric population sizes, and government initiatives to strengthen infectious disease detection networks in countries like China, India, and Japan. Meanwhile, emerging markets in Latin America and the Middle East & Africa are gaining momentum as they invest in upgrading laboratory capabilities and increasing RSV testing coverage to address both seasonal and epidemic surges.

Major market player included in this report are:
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• BioMérieux SA
• QuidelOrtho Corporation
• Siemens Healthineers AG
• BD (Becton, Dickinson and Company)
• Hologic, Inc.
• PerkinElmer Inc.
• Meridian Bioscience, Inc.
• Luminex Corporation
• Cepheid (a Danaher company)
• DiaSorin S.p.A.
• GenMark Diagnostics, Inc.

Global RSV Diagnostics Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Product:
• Kits and Assays
• Instruments

By Method:
• Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA)
• Molecular Diagnostic

By End User:
• Hospitals & Clinics
• Clinical Laboratories
• Homecare

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more